Privia Health Group (NASDAQ:PRVA) CEO Parth Mehrotra Sells 27,229 Shares

Privia Health Group, Inc. (NASDAQ:PRVA) CEO Parth Mehrotra sold 27,229 shares of Privia Health Group stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $21.52, for a total value of $585,968.08. Following the completion of the transaction, the chief executive officer owned 581,952 shares in the company, valued at $12,523,607.04. This trade represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Parth Mehrotra also recently made the following trade(s):

• On Thursday, March 12th, Parth Mehrotra sold 26,763 shares of Privia Health Group stock. The stock was sold at an average price of $21.90, for a total value of $586,109.70.
• On Tuesday, March 10th, Parth Mehrotra sold 21,097 shares of Privia Health Group stock. The stock was sold at an average price of $22.71, for a total value of $479,112.87.
• On Monday, March 9th, Parth Mehrotra sold 41,999 shares of Privia Health Group stock. The shares were sold at an average price of $22.86, for a total transaction of $960,097.14.
• On Friday, March 6th, Parth Mehrotra sold 21,440 shares of Privia Health Group stock. The shares were sold at an average price of $23.15, for a total transaction of $496,336.00.

Privia Health Group Stock Performance

Privia Health Group stock traded up $0.28 during trading hours on Monday, reaching $21.96. 633,287 shares of the stock were exchanged, compared to its average volume of 805,784. Privia Health Group, Inc. has a 52-week low of $18.77 and a 52-week high of $26.51. The stock has a market cap of $2.72 billion, a P/E ratio of 129.18, a P/E/G ratio of 1.37 and a beta of 0.82. The firm’s 50 day moving average is $22.89 and its 200 day moving average is $23.61.

Privia Health Group (NASDAQ:PRVA) last issued its earnings results on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.21. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The business had revenue of $541.17 million for the quarter, compared to the consensus estimate of $516.61 million. During the same quarter in the previous year, the firm earned $0.21 earnings per share. The business’s quarterly revenue was up 17.4% compared to the same quarter last year. Equities research analysts expect that Privia Health Group, Inc. will post 0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Privia Health Group

Institutional investors have recently modified their holdings of the company. Van Berkom & Associates Inc. grew its holdings in shares of Privia Health Group by 30.1% in the 3rd quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company’s stock worth $93,987,000 after acquiring an additional 873,344 shares during the period. Vanguard Group Inc. raised its holdings in Privia Health Group by 5.3% during the third quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock worth $301,263,000 after purchasing an additional 607,447 shares during the last quarter. ArrowMark Colorado Holdings LLC boosted its position in Privia Health Group by 139.4% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company’s stock worth $19,946,000 after purchasing an additional 489,866 shares in the last quarter. Algert Global LLC boosted its position in Privia Health Group by 277.4% during the third quarter. Algert Global LLC now owns 484,304 shares of the company’s stock worth $12,059,000 after purchasing an additional 355,966 shares in the last quarter. Finally, Freestone Grove Partners LP grew its holdings in Privia Health Group by 40.6% in the fourth quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company’s stock valued at $28,768,000 after purchasing an additional 350,194 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on PRVA shares. Citigroup dropped their target price on Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Stephens restated an “overweight” rating and issued a $32.00 price target on shares of Privia Health Group in a research note on Thursday, December 4th. Jefferies Financial Group reaffirmed a “buy” rating and set a $32.00 price objective on shares of Privia Health Group in a report on Thursday, February 26th. Canaccord Genuity Group raised their target price on Privia Health Group from $34.00 to $35.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Wolfe Research set a $31.00 target price on shares of Privia Health Group in a research report on Tuesday, January 6th. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Privia Health Group currently has an average rating of “Moderate Buy” and an average target price of $31.00.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.